Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Cagrilintide/semaglutide

RAMBO

Novo Nordisk · Phase 1 · Recruiting · Enrollment 144

NCT07010432

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Cagrilintiden/rn/rn/rn/r
Semaglutiden/rn/rn/rn/r
CagriSeman/rn/rn/rn/r
Placebon/rn/rn/rn/r

Not shown

  • Cagrilintide: endpoint not reported
  • Semaglutide: endpoint not reported
  • CagriSema: endpoint not reported
  • Placebo: endpoint not reported